Population genomic screening of young adults for familial hypercholesterolaemia: a cost-effectiveness analysis
The aim of this study was to assess the impact and cost-effectiveness of offering population genomic screening to all young adults in Australia to detect heterozygous familial hypercholesterolaemia (FH). We designed a decision analytic Markov model to compare the current standard of care for heteroz...
Gespeichert in:
| Veröffentlicht in: | European heart journal Jg. 43; H. 34; S. 3243 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
England
07.09.2022
|
| Schlagworte: | |
| ISSN: | 1522-9645, 1522-9645 |
| Online-Zugang: | Weitere Angaben |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | The aim of this study was to assess the impact and cost-effectiveness of offering population genomic screening to all young adults in Australia to detect heterozygous familial hypercholesterolaemia (FH).
We designed a decision analytic Markov model to compare the current standard of care for heterozygous FH diagnosis in Australia (opportunistic cholesterol screening and genetic cascade testing) with the alternate strategy of population genomic screening of adults aged 18-40 years to detect pathogenic variants in the LDLR/APOB/PCSK9 genes. We used a validated cost-adaptation method to adapt findings to eight high-income countries. The model captured coronary heart disease (CHD) morbidity/mortality over a lifetime horizon, from healthcare and societal perspectives. Risk of CHD, treatment effects, prevalence, and healthcare costs were estimated from published studies. Outcomes included quality-adjusted life years (QALYs), costs and incremental cost-effectiveness ratio (ICER), discounted 5% annually. Sensitivity analyses were undertaken to explore the impact of key input parameters on the robustness of the model. Over the lifetime of the population (4 167 768 men; 4 129 961 women), the model estimated a gain of 33 488years of life lived and 51 790 QALYs due to CHD prevention. Population genomic screening for FH would be cost-effective from a healthcare perspective if the per-test cost was ≤AU$250, yielding an ICER of <AU$28 000 per QALY gained. From a societal perspective, population genomic screening would be cost-saving. ICERs from societal perspective remained cost-saving after adaptation to other countries.
Based on our model, offering population genomic screening to all young adults for FH could be cost-effective, at testing costs that are feasible. |
|---|---|
| AbstractList | The aim of this study was to assess the impact and cost-effectiveness of offering population genomic screening to all young adults in Australia to detect heterozygous familial hypercholesterolaemia (FH).
We designed a decision analytic Markov model to compare the current standard of care for heterozygous FH diagnosis in Australia (opportunistic cholesterol screening and genetic cascade testing) with the alternate strategy of population genomic screening of adults aged 18-40 years to detect pathogenic variants in the LDLR/APOB/PCSK9 genes. We used a validated cost-adaptation method to adapt findings to eight high-income countries. The model captured coronary heart disease (CHD) morbidity/mortality over a lifetime horizon, from healthcare and societal perspectives. Risk of CHD, treatment effects, prevalence, and healthcare costs were estimated from published studies. Outcomes included quality-adjusted life years (QALYs), costs and incremental cost-effectiveness ratio (ICER), discounted 5% annually. Sensitivity analyses were undertaken to explore the impact of key input parameters on the robustness of the model. Over the lifetime of the population (4 167 768 men; 4 129 961 women), the model estimated a gain of 33 488years of life lived and 51 790 QALYs due to CHD prevention. Population genomic screening for FH would be cost-effective from a healthcare perspective if the per-test cost was ≤AU$250, yielding an ICER of <AU$28 000 per QALY gained. From a societal perspective, population genomic screening would be cost-saving. ICERs from societal perspective remained cost-saving after adaptation to other countries.
Based on our model, offering population genomic screening to all young adults for FH could be cost-effective, at testing costs that are feasible. The aim of this study was to assess the impact and cost-effectiveness of offering population genomic screening to all young adults in Australia to detect heterozygous familial hypercholesterolaemia (FH).AIMSThe aim of this study was to assess the impact and cost-effectiveness of offering population genomic screening to all young adults in Australia to detect heterozygous familial hypercholesterolaemia (FH).We designed a decision analytic Markov model to compare the current standard of care for heterozygous FH diagnosis in Australia (opportunistic cholesterol screening and genetic cascade testing) with the alternate strategy of population genomic screening of adults aged 18-40 years to detect pathogenic variants in the LDLR/APOB/PCSK9 genes. We used a validated cost-adaptation method to adapt findings to eight high-income countries. The model captured coronary heart disease (CHD) morbidity/mortality over a lifetime horizon, from healthcare and societal perspectives. Risk of CHD, treatment effects, prevalence, and healthcare costs were estimated from published studies. Outcomes included quality-adjusted life years (QALYs), costs and incremental cost-effectiveness ratio (ICER), discounted 5% annually. Sensitivity analyses were undertaken to explore the impact of key input parameters on the robustness of the model. Over the lifetime of the population (4 167 768 men; 4 129 961 women), the model estimated a gain of 33 488years of life lived and 51 790 QALYs due to CHD prevention. Population genomic screening for FH would be cost-effective from a healthcare perspective if the per-test cost was ≤AU$250, yielding an ICER of <AU$28 000 per QALY gained. From a societal perspective, population genomic screening would be cost-saving. ICERs from societal perspective remained cost-saving after adaptation to other countries.METHODS AND RESULTSWe designed a decision analytic Markov model to compare the current standard of care for heterozygous FH diagnosis in Australia (opportunistic cholesterol screening and genetic cascade testing) with the alternate strategy of population genomic screening of adults aged 18-40 years to detect pathogenic variants in the LDLR/APOB/PCSK9 genes. We used a validated cost-adaptation method to adapt findings to eight high-income countries. The model captured coronary heart disease (CHD) morbidity/mortality over a lifetime horizon, from healthcare and societal perspectives. Risk of CHD, treatment effects, prevalence, and healthcare costs were estimated from published studies. Outcomes included quality-adjusted life years (QALYs), costs and incremental cost-effectiveness ratio (ICER), discounted 5% annually. Sensitivity analyses were undertaken to explore the impact of key input parameters on the robustness of the model. Over the lifetime of the population (4 167 768 men; 4 129 961 women), the model estimated a gain of 33 488years of life lived and 51 790 QALYs due to CHD prevention. Population genomic screening for FH would be cost-effective from a healthcare perspective if the per-test cost was ≤AU$250, yielding an ICER of <AU$28 000 per QALY gained. From a societal perspective, population genomic screening would be cost-saving. ICERs from societal perspective remained cost-saving after adaptation to other countries.Based on our model, offering population genomic screening to all young adults for FH could be cost-effective, at testing costs that are feasible.CONCLUSIONBased on our model, offering population genomic screening to all young adults for FH could be cost-effective, at testing costs that are feasible. |
| Author | Marquina, Clara Zoungas, Sophia Lacaze, Paul Pang, Jing Tiller, Jane Nelson, Mark R Liew, Danny Riaz, Moeen Watts, Gerald F Sturm, Amy C McNeil, John Ademi, Zanfina Nicholls, Stephen J Ference, Brian A |
| Author_xml | – sequence: 1 givenname: Clara orcidid: 0000-0003-2582-0374 surname: Marquina fullname: Marquina, Clara organization: School of Public Health and Preventive Medicine, Monash University, 553 St Kilda Rd, Melbourne, VIC 3004, Australia – sequence: 2 givenname: Paul orcidid: 0000-0002-0902-6798 surname: Lacaze fullname: Lacaze, Paul organization: School of Public Health and Preventive Medicine, Monash University, 553 St Kilda Rd, Melbourne, VIC 3004, Australia – sequence: 3 givenname: Jane orcidid: 0000-0003-3906-6632 surname: Tiller fullname: Tiller, Jane organization: School of Public Health and Preventive Medicine, Monash University, 553 St Kilda Rd, Melbourne, VIC 3004, Australia – sequence: 4 givenname: Moeen surname: Riaz fullname: Riaz, Moeen organization: School of Public Health and Preventive Medicine, Monash University, 553 St Kilda Rd, Melbourne, VIC 3004, Australia – sequence: 5 givenname: Amy C orcidid: 0000-0001-6839-7786 surname: Sturm fullname: Sturm, Amy C organization: Genomic Medicine Institute, 100 North Academy Avenue, Geisinger, PA 17822, USA – sequence: 6 givenname: Mark R surname: Nelson fullname: Nelson, Mark R organization: Menzies Institute for Medical Research, 17 Liverpool St, Hobart, TAS 7000, Australia – sequence: 7 givenname: Brian A surname: Ference fullname: Ference, Brian A organization: University of Cambridge, Centre for Naturally Randomised Trials, The Old Schools, Trinity Ln, Cambridge CB2 1TN, UK – sequence: 8 givenname: Jing orcidid: 0000-0002-9700-6948 surname: Pang fullname: Pang, Jing organization: School of Medicine, Faculty of Health and Medical Sciences, University of Western Australia, 35 Stirling Hwy, Perth, WA 6009, Australia – sequence: 9 givenname: Gerald F surname: Watts fullname: Watts, Gerald F organization: Lipid Disorders Clinic, Cardiometabolic Service, Department of Internal Medicine, Royal Perth Hospital, Victoria Square, Perth, WA 6000, Australia – sequence: 10 givenname: Stephen J surname: Nicholls fullname: Nicholls, Stephen J organization: School of Public Health and Preventive Medicine, Monash University, 553 St Kilda Rd, Melbourne, VIC 3004, Australia – sequence: 11 givenname: Sophia surname: Zoungas fullname: Zoungas, Sophia organization: School of Public Health and Preventive Medicine, Monash University, 553 St Kilda Rd, Melbourne, VIC 3004, Australia – sequence: 12 givenname: Danny orcidid: 0000-0002-0131-623X surname: Liew fullname: Liew, Danny organization: School of Public Health and Preventive Medicine, Monash University, 553 St Kilda Rd, Melbourne, VIC 3004, Australia – sequence: 13 givenname: John orcidid: 0000-0002-1049-5129 surname: McNeil fullname: McNeil, John organization: School of Public Health and Preventive Medicine, Monash University, 553 St Kilda Rd, Melbourne, VIC 3004, Australia – sequence: 14 givenname: Zanfina orcidid: 0000-0002-0625-3522 surname: Ademi fullname: Ademi, Zanfina organization: School of Public Health and Preventive Medicine, Monash University, 553 St Kilda Rd, Melbourne, VIC 3004, Australia |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34788414$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkM1KxDAYRYOMOD_6AG4kSzd1krZpWncy-AcDutB1-Zp-mWZIkzFphb69A47g6p7F4XK5SzJz3iEh15zdcVZlaxxDhxCG_Ro7aKRkZ2TBRZomVZGL2T-ek2WMe8ZYWfDigsyzXJZlzvMFce_-MFoYjHd0h873RtGoAqIzbke9ppMfjwDtaIdItQ9UQ2-sAUu76YBBdd5iHDB4C9gbuKdAlY9DglqjGsw3OoyRggM7RRMvybkGG_HqlCvy-fT4sXlJtm_Pr5uHbaKyQg5J1XKpWKNR5pqVLWuyFKCVmWSctZlIdcmLSgjdgFY5UzIVpZSZAmy1bqRo0hW5_e09BP81HgfWvYkKrQWHfox1KqqKSVbk_KjenNSx6bGtD8H0EKb676P0B32-cGM |
| CitedBy_id | crossref_primary_10_1111_jpc_16096 crossref_primary_10_3390_cardiogenetics14020005 crossref_primary_10_1093_eurheartj_ehad773 crossref_primary_10_1016_j_atherosclerosis_2025_120447 crossref_primary_10_1007_s40274_021_08249_9 crossref_primary_10_3389_fgene_2025_1589014 crossref_primary_10_1136_bmjopen_2023_082699 crossref_primary_10_1186_s41256_024_00382_x crossref_primary_10_1161_CIRCGEN_122_003816 crossref_primary_10_1016_j_atherosclerosis_2025_119218 crossref_primary_10_1016_j_jacadv_2023_100333 crossref_primary_10_1097_MED_0000000000000904 crossref_primary_10_3389_fgene_2022_893832 crossref_primary_10_1093_eurheartj_ehac479 crossref_primary_10_1016_j_urolonc_2024_09_016 crossref_primary_10_1093_eurheartj_ehab869 crossref_primary_10_1161_JAHA_121_025192 crossref_primary_10_1093_eurheartj_ehad224 crossref_primary_10_5694_mja2_51454 crossref_primary_10_1186_s12916_025_03966_7 crossref_primary_10_1007_s40273_023_01347_7 crossref_primary_10_5551_jat_RV22031 crossref_primary_10_1007_s11883_023_01094_2 crossref_primary_10_1093_jalm_jfad093 crossref_primary_10_1161_CIRCGEN_122_003842 crossref_primary_10_1016_j_hlc_2023_09_012 crossref_primary_10_1001_jamapediatrics_2023_0771 |
| ContentType | Journal Article |
| Copyright | Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2021. For permissions, please email: journals.permissions@oup.com. |
| Copyright_xml | – notice: Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2021. For permissions, please email: journals.permissions@oup.com. |
| DBID | NPM 7X8 |
| DOI | 10.1093/eurheartj/ehab770 |
| DatabaseName | PubMed MEDLINE - Academic |
| DatabaseTitle | PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1522-9645 |
| ExternalDocumentID | 34788414 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: Australian National Heart Foundation and Monash University Faculty of Medicine, Nursing and Health Sciences – fundername: National Heart Foundation Future Leader Fellowship grantid: 102604 |
| GroupedDBID | --- -E4 .2P .I3 .XZ .ZR 08P 0R~ 18M 1TH 29G 2WC 4.4 482 48X 53G 5GY 5RE 5VS 5WA 5WD 70D AABZA AACZT AAJKP AAMVS AAOGV AAPNW AAPQZ AAPXW AARHZ AAUAY AAVAP ABDFA ABEJV ABEUO ABGNP ABIXL ABJNI ABKDP ABNHQ ABNKS ABOCM ABPTD ABQLI ABQNK ABVGC ABWST ABXVV ABZBJ ACGFO ACGFS ACPRK ACUFI ACUTJ ACUTO ACYHN ADBBV ADEYI ADEZT ADGZP ADHKW ADHZD ADIPN ADJQC ADOCK ADQBN ADRIX ADRTK ADVEK ADYVW ADZXQ AEGPL AEGXH AEJOX AEKSI AEMDU AENEX AENZO AEPUE AETBJ AEWNT AFFZL AFIYH AFOFC AFXAL AFXEN AGINJ AGKEF AGQXC AGSYK AGUTN AHMBA AHMMS AHXPO AIAGR AIJHB AJEEA ALMA_UNASSIGNED_HOLDINGS ALUQC APIBT APWMN ATGXG AXUDD BAWUL BAYMD BCGUY BCRHZ BEYMZ BHONS BTRTY BVRKM C45 CDBKE CS3 CZ4 DAKXR DIK DILTD D~K E3Z EBS EE~ EMOBN ENERS F5P F9B FECEO FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H13 H5~ HAR HW0 HZ~ IOX J21 KAQDR KBUDW KOP KQ8 KSI KSN L7B M-Z M41 M49 MHKGH ML0 N9A NGC NOMLY NOYVH NPM NU- O9- OAUYM OAWHX OB3 OCZFY ODMLO OGROG OJQWA OJZSN OK1 OPAEJ OVD OWPYF P2P PAFKI PEELM PQQKQ Q1. Q5Y R44 RD5 ROL ROX RUSNO RW1 RXO SEL TCURE TEORI TJX W8F WOQ X7H YAYTL YKOAZ YXANX ZKX ~91 7X8 AAFWJ ABPQP ADNBA AEMQT AFYAG AHGBF AJBYB AJNCP ALXQX JXSIZ |
| ID | FETCH-LOGICAL-c367t-9d17c0bfe74f08d0b32aad737010d352f816955fbafc40c7258773caedffb75b2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 31 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000790098100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1522-9645 |
| IngestDate | Sun Sep 28 02:17:08 EDT 2025 Wed Feb 19 02:28:17 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 34 |
| Keywords | Prevention Cost-effectiveness analysis Population genomic screening Familial hypercholesterolaemia |
| Language | English |
| License | Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2021. For permissions, please email: journals.permissions@oup.com. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c367t-9d17c0bfe74f08d0b32aad737010d352f816955fbafc40c7258773caedffb75b2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0003-3906-6632 0000-0002-0131-623X 0000-0002-0902-6798 0000-0003-2582-0374 0000-0002-1049-5129 0000-0001-6839-7786 0000-0002-0625-3522 0000-0002-9700-6948 |
| PMID | 34788414 |
| PQID | 2599070641 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2599070641 pubmed_primary_34788414 |
| PublicationCentury | 2000 |
| PublicationDate | 2022-09-07 |
| PublicationDateYYYYMMDD | 2022-09-07 |
| PublicationDate_xml | – month: 09 year: 2022 text: 2022-09-07 day: 07 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | European heart journal |
| PublicationTitleAlternate | Eur Heart J |
| PublicationYear | 2022 |
| References | 34977918 - Eur Heart J. 2022 Jan 03 |
| References_xml | – reference: 34977918 - Eur Heart J. 2022 Jan 03;: |
| SSID | ssj0008616 |
| Score | 2.533287 |
| Snippet | The aim of this study was to assess the impact and cost-effectiveness of offering population genomic screening to all young adults in Australia to detect... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 3243 |
| Title | Population genomic screening of young adults for familial hypercholesterolaemia: a cost-effectiveness analysis |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/34788414 https://www.proquest.com/docview/2599070641 |
| Volume | 43 |
| WOSCitedRecordID | wos000790098100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3LSsNAFB3Uirjx_agvRnA7NO-bcSMiFjctXSh0V-ZxBys0qU0r-PfeSVNdCYKb7AJhcnLuuXMn5zB242syaIsitRpFYjIU0shcOLRoAmNRW1eHTUC_nw-HctBsuFXNscoVJ9ZEbUvj98g7JNOpj6MCGt5N34VPjfLT1SZCY521YpIyHtUw_HELz7M6-pRKVCRklqSrqaaMO7iY-cTo-VvHG2IDBL8rzLrSdHf_-4x7bKfRmPx-CYp9tobFAdvqNVP0Q1YMvlO7uPdonYwNJ_agjpbqGC8d__QUwGtrjoqTquX1Ngghlb9S2zrzjFkbLFBbjJOxuuWKm7Kai-XhkIY_uWr8To7YS_fx-eFJNLkLwsQZzIW0IZhAO4TEBbkNdBwpZSEG6t0sCTaXh5lMU6eVM0lgIEpzgNgotM5pSHV0zDaKssBTxkOrcwWYWUSXxAmqXLoMSIIRFCRGus2uVys5Ilz7YYUqsFxUo5-1bLOT5esYTZcGHKPYe_4nYXL2h7vP2Xbk_1jwMyC4YC1HXzVesk3zMR9Xs6saMHTtD3pfLo7R4g |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Population+genomic+screening+of+young+adults+for+familial+hypercholesterolaemia%3A+a+cost-effectiveness+analysis&rft.jtitle=European+heart+journal&rft.au=Marquina%2C+Clara&rft.au=Lacaze%2C+Paul&rft.au=Tiller%2C+Jane&rft.au=Riaz%2C+Moeen&rft.date=2022-09-07&rft.eissn=1522-9645&rft_id=info:doi/10.1093%2Feurheartj%2Fehab770&rft_id=info%3Apmid%2F34788414&rft_id=info%3Apmid%2F34788414&rft.externalDocID=34788414 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1522-9645&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1522-9645&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1522-9645&client=summon |